TORONTO, Jan. 16, 2019 /CNW/ - Pure Global Cannabis Inc. (TSX.V:PURE;OTC: PRCNF; FRA:1QS) (the "Company" or "Pure Global" an integrated, growth-oriented life sciences and consumer products cannabis company, through its subsidiary PureSinse Inc. ("PureSinse"), announces the launch of the Clinical Cannabinoid Education Network, CCEN.ca, a not-for-profit, to educate and inform physicians about the latest breakthroughs related to medical cannabis.
The Clinical Cannabinoid Education Network (CCEN) provides an educational platform for medical practitioners who want to learn more about the science of cannabis and its place in their clinical practice. By providing education and a forum for physicians by physicians, they can share new information and learn from one another in a supportive environment. This will allow more patients to obtain the latest and most effective treatments as determined by their doctors, including safe access to medical cannabis.
Run jointly as a partnership initiative between Spark Cannabis and PureSinse, the CCEN launch features an initial networking dinner on January 31, 2019 and a full summit on May 10, 2019. Please visit CCEN.ca to register.
On the CCEN advisory board is Dr. Sanjeev Goel. Dr. Goel is a practicing family physician in Brampton, Ontario, the Chief Medical Officer for PureSinse, and the medical director for Spark Cannabis. Dr. Goel has extensive experience in medical cannabis and has been a pioneer in the field since 2015. Dr. Goel was also founder and CEO for an integrative medical practice using cutting-edge medical treatments for patients across the country. "We need an education network like this," says Dr. Goel. "By giving doctors an opportunity to learn about medical cannabis from each other, patients will be able to benefit from more effective treatments overall."
For more information about CCEN, or to register for the networking dinner and the summit, please visit CCEN.ca.
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSX.V:PURE;OTC: PRCNF; FRA:1QS) is an innovation-based cannabis Company led by experienced pharma, biotechnology, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company's wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act, 2017. The Company's Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. PURE will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates. The Company is using the Canadian market as a springboard to develop and manufacture GMP-compliant cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global's future plans and intentions. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Pure Global Cannabis Inc.
For further information: regarding Pure Global, please contact: Stephen Pynn, VP Corporate Development, Telephone: 1-866-840-PURE (7873), E-mail: email@example.com; Malay (Mel) Panchal, President & CEO, Telephone: 1-866-840-PURE (7873), E-mail: firstname.lastname@example.org